FARMACOLOGIA DE LOS HIPOLIPEMIANTES PDF

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hiperlipidemia. Am J Cardiol, ; 80 5 : Bertram G. Effects of hormone replacement therapy on serum lipids in elderly women, a randomized, placebocontrolled trial. Ann Intern Med, ; Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Author:Bracage Douzilkree
Country:Singapore
Language:English (Spanish)
Genre:Music
Published (Last):25 April 2004
Pages:330
PDF File Size:13.32 Mb
ePub File Size:11.76 Mb
ISBN:296-5-39073-865-9
Downloads:62499
Price:Free* [*Free Regsitration Required]
Uploader:Arashigar



Statins are lipid lowering agents that promote their effects on plasma lipids through the inhibition of HMG-CoA reductase, a crucial enzyme in the cascade of cholesterol synthesis, leading to reduction of tissue cholesterol pool and consequently, to an upregulation of the LDL receptor expression.

There are considerable differences among statins regarding some pharmacokinetic properties, such as the coefficient of hydrophilicity, via liver metabolism especially regarding P cytochrome and isoenzymes , plasma half-life and efficacy of serum lipid changes.

They may also differ regarding interactions with other drugs that share the same pathway of metabolism. Recently, many pleiotropic effects have been reported with these drugs, such as anti-inflammatory properties, improvement in endothelial function and benefits on hemostasis. Key words: Statins, pharmacokinetics, drug interactions. Figura 5. Ballantyne CM. Clinical trial endpoints: angiograms, events, and plaque instability.

Am J Cardiol. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Polymorphisms in human MDR1 P-glycoprotein : recent advances and clinical relevance. Cerivastatin and reports of fatal rhabdomyolysis. HMG reductase inhibitors and myotoxicity. Bliznakov EG.

Lipid-lowering drugs statins , cholesterol, and coenzyme Q The Baycol case a modern Pandora's box. Rosenson RS. Current overview of statin-induced myopathy. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P inhibitors.

FDA adverse event reports on statin-associated rhabdomylolysis. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Simvastatin-fluconazole causing rhabdomyolysis. Duration of effect of grapefruit on the pharmacokinetics of the CYP3A4 substrate simvastatin.

Safety of statins. Focus on clinical and pharmacokinetics and drug interactions. Effects of fibrates on metabolism of statins in human hepatocytes. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.

Pleiotropic effects of statins: lipid reduction and beyond. Liao JK. Statin therapy for cardiac hypertrophy and heart failure. J Investig Med. Metaanalysis of statins and survival in de novo cardiac transplantation.

A novel anti-inflammatory role for simvastatin in inflammatory arthritis. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study CARDS : multicentre randomised placebo-controlled trial. Statins inhibit HIV-1 infection by down-regulating Rho activity. HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture? Drugs Aging ; Services on Demand Journal. All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License.

How to cite this article.

MAFATIH JINAN PDF

2013, Número 607

Statins are lipid lowering agents that promote their effects on plasma lipids through the inhibition of HMG-CoA reductase, a crucial enzyme in the cascade of cholesterol synthesis, leading to reduction of tissue cholesterol pool and consequently, to an upregulation of the LDL receptor expression. There are considerable differences among statins regarding some pharmacokinetic properties, such as the coefficient of hydrophilicity, via liver metabolism especially regarding P cytochrome and isoenzymes , plasma half-life and efficacy of serum lipid changes. They may also differ regarding interactions with other drugs that share the same pathway of metabolism. Recently, many pleiotropic effects have been reported with these drugs, such as anti-inflammatory properties, improvement in endothelial function and benefits on hemostasis.

MAJALAH COMMANDO PDF

Vademécum Académico de Medicamentos

Hypolipidemic agents drug interactions: approach to establish and assess its clinical significance. Structured review. Franco 1,4 , Y. Henao 1 , M. Monsalve 1,4 , F. Amariles 1,2,4. Universidad de Antioquia.

Related Articles